About the Event
Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) is developing therapies for recurrent pericarditis and acute myocarditis; both are potential billion-dollar markets for which there are few or no suitable alternative treatment options.
Join our webinar with Cardiol’s President & CEO, David Elsley, for more information on their Phase 2 Clinical Trial programs and the major inflection points in the company’s near future.